Abstract
The clinical usefulness of feprazone on osteoarthritis was examined by a multicenter double-blind comparative study dosing feprazone (300mg/day) and diclofenac sodium (75mg/day).
(1) Both feprazone and diclofenac sodium showed a high improvement rate in efficacy: 81.4% and 82.5% respectively.
(2) The incidence of side effects was 6.7% in feprazone treated group and 13.1% in diclofenac sodium treated group, however, no statistically significant difference was found.
(3) Feprazone was 83.3% and diclofenac sodium was 77.0% in usefulness, however, no statistically significant difference was found.
Consequently, feprazone was assessed to be equal in efficacy and slightly safer to use than dicrofenac sodium in the treatment of osteoarthritis.
